Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hypothyroidism

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    134 result(s) found for: Hypothyroidism. Displaying page 3 of 7.
    « Previous 1  2  3  4  5  6  7  Next»
    EudraCT Number: 2007-001107-38 Sponsor Protocol Number: SESCHI.26371 Start Date*: 2008-05-26
    Sponsor Name:Cefak KG
    Full Title: Dose finding study to investigate efficacy and tolerability of a 6 month oral treatment with selenium in patients with autoimmune thyroiditis: prospective, controlled parallel group study with Cef...
    Medical condition: Autoimmune thyroiditis (Hashimoto-thyroiditis)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10014698 - Endocrine disorders 10019167 Hashimoto's thyroiditis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002260-31 Sponsor Protocol Number: GINECO-OV243b Start Date*: 2020-10-01
    Sponsor Name:ARCAGY-GINECO
    Full Title: Multicentric non-randomized phase II of pembrolizumab in combination with etoposide-cisplatin-based chemotherapy in first-line advanced small cell ovarian carcinoma of hypercalcemic type
    Medical condition: Advanced small cell ovarian carcinoma of hypercalcemic type
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070908 Ovarian cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070907 Ovarian cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070906 Ovarian cancer stage II PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-014767-40 Sponsor Protocol Number: S203.2.009 Start Date*: 2009-11-20
    Sponsor Name:Abbott Biologicals B.V.
    Full Title: Randomized, Double-Blind, Active-Controlled Trial to Assess the Safety and Immunogenicity of Solvay's Cell-Derived Influenza Vaccine, Including Revaccination, in Elderly subjects.
    Medical condition: Prophylaxsis of seasonal influenza
    Disease: Version SOC Term Classification Code Term Level
    12.0 10022005 Influenza viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) EE (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2008-006176-30 Sponsor Protocol Number: NW-1029/01-08 Start Date*: 2009-03-13
    Sponsor Name:Newron Pharmaceuticals S.p.A.
    Full Title: EFFICACY AND SAFETY OF TWO FIXED DOSES (160 OR 320 MG/DAY) OF RALFINAMIDE IN PATIENTS WITH CHRONIC NEUROPATHIC LOW BACK PAIN. A MULTICENTER, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED 12- WEEK ST...
    Medical condition: Chronic neuropathic low back pain.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) DE (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001369-28 Sponsor Protocol Number: 880 Start Date*: 2014-10-30
    Sponsor Name:Gateshead Health NHS Foundation Trust
    Full Title: THYRoxine in Acute Myocardial Infarction (ThyrAMI)
    Medical condition: Hypothyroidism and Acute Myocardial Infarction
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10000891 Acute myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-002408-15 Sponsor Protocol Number: Ipi4 Start Date*: 2013-11-05
    Sponsor Name:Oslo University Hospital
    Full Title: Phase IV ipilimumab in melanoma A National, Multicenter, Interventional Study in Patients with Unresectable or Metastatic Melanoma
    Medical condition: Patients diagnosed with unresectable or metastatic melanoma, cutaneous, ocular, mucosal and unknown primary tumor
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-018014-20 Sponsor Protocol Number: COSAKV1 Start Date*: 2010-04-19
    Sponsor Name:Common Services Agency
    Full Title: A Randomised Phase II Study Evaluating Cediranib vs. Cediranib and Saracatanib in patients with relapsed metastatic clear cell renal cancer
    Medical condition: Clear Cell Renal Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-002780-34 Sponsor Protocol Number: 13VR3 Start Date*: 2016-11-10
    Sponsor Name:Versartis, Inc.
    Full Title: An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children with Growth Hormone Deficiency The VISTA Study: Versartis Long-Term Safety Study of So...
    Medical condition: Growth hormone deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) BE (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001158-33 Sponsor Protocol Number: OZR-2016-34 Start Date*: 2017-07-20
    Sponsor Name:The Rotterdam Eye Hospital
    Full Title: A pilot study towards a therapy with prednisolone encapsulated liposomes for the treatment of Graves’ Orbitopathy with reduced systemic steroid exposure
    Medical condition: Graves' Orbitopathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-003099-39 Sponsor Protocol Number: LWH0604 Start Date*: 2008-08-21
    Sponsor Name:Liverpool Women's NHS Foundation Trust Hospital
    Full Title: A Randomised Controlled Trial of Thyroxine in Preterm Infants Under 28 weeks' Gestation.
    Medical condition: Hypothyroidism is a condition where there is a lack of thyroid hormone in the body. Thyroid hormones are important for normal brain development and growth. Children who are born with low thyroid ho...
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001157-27 Sponsor Protocol Number: 2017_52-REGALIA Start Date*: 2018-11-22
    Sponsor Name:CHRU of Lille
    Full Title: Reversing poor graft function with eltrombopag after allogeneIc hematopoietic cell transplantation : a prospective, phase II study by the SFGM-TC.
    Medical condition: Poor Graft Function (PGF) after allogeneic hematopoietic cell transplantation (allo-HCT). PGF is commonly defined as follows: one or several significant cytopenias after allo-HCT persisting or deve...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-005458-97 Sponsor Protocol Number: VAC18193RSV3001 Start Date*: 2021-10-28
    Sponsor Name:Janssen Vaccines & Prevention B.V.
    Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of an Ad26.RSV.preF-based Vaccine in the Prevention of Lower Respiratory Tract Disease Caused by RSV in Adults Aged 60 Years an...
    Medical condition: Prevention of Lower Respiratory Tract Disease Caused by The respiratory syncytial virus (RSV)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004045-16 Sponsor Protocol Number: ET18-272 Start Date*: 2019-03-14
    Sponsor Name:Centre Léon Bérard
    Full Title: REGOSTA – A randomized, placebo-controlled, double-blinded, multicentre study evaluating the efficacy and safety of regorafenib as maintenance therapy after first-line treatment in patients with bo...
    Medical condition: Patients with bone sarcomas other than Ewing sarcoma or chondrosarcoma or chordoma, who have no residual disease after neoadjuvant chemotherapy, surgery and/or adjuvant chemotherapy.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002127-26 Sponsor Protocol Number: BAFFI_14 Start Date*: 2015-10-13
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
    Full Title: Randomized, single-blind, controlled study of the anti-BAFF antibody belimumab or methylprednisolone treatment in hyperthyroid Graves' disease (GD) and active orbitopathy (GO)
    Medical condition: GRAVES' ORBITOPATHY
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057889 Graves' ophthalmopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002790-22 Sponsor Protocol Number: ML39921 Start Date*: 2019-04-11
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
    Full Title: Tocilizumab in Graves’ Orbitopathy (TOGO). Multicenter, randomized, observer-blind, controlled study of the anti-IL-6 receptor antibody tocilizumab (TCZ) or methylprednisolone (MP) treatment in pat...
    Medical condition: Active moderate-severe Graves' Orbitopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10015684 Exophthalmos endocrine LLT
    20.1 100000004853 10014702 Endocrine exophthalmos LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001038-28 Sponsor Protocol Number: S201.3.127 Start Date*: 2008-05-27
    Sponsor Name:Solvay Biologicals BV
    Full Title: Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac® for the Season 2008/2009. An Open-Label, Baseline-Controlled Multi-Center Study in Two Groups: Adult S...
    Medical condition: Prophylaxis of Influenza
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022005 Influenza viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-010900-27 Sponsor Protocol Number: S201.3.128 Start Date*: 2009-05-08
    Sponsor Name:Solvay Biologicals BV
    Full Title: Immunogenicity, reactogenicity and safety of the trivalent influenza subunit vaccine Influvac® for the season 2009/2010. An open-label, baseline-controlled multi-center study in two groups: adult s...
    Medical condition: Prophylaxis of Influenza
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022005 Influenza viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-018350-13 Sponsor Protocol Number: S201.3.130 Start Date*: 2010-05-12
    Sponsor Name:Abbott Biologicals B.V.
    Full Title: Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac® for the Season 2010/2011. An Open-Label, Baseline-Controlled Multi-Center Study in Two Groups: Adult S...
    Medical condition: Prophylaxis of Influenza
    Disease: Version SOC Term Classification Code Term Level
    12.1 10022005 Influenza viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001483-38 Sponsor Protocol Number: BAY1163877/19131 Start Date*: 2019-09-02
    Sponsor Name:Bayer AG
    Full Title: An international, multicenter, Phase 1b/2 study of rogaratinib (BAY 1163877) in combination with atezolizumab as first-line treatment in cisplatin-ineligible patients with FGFR-positive locally adv...
    Medical condition: FGFR-positive locally advanced or metastatic urothelial carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001941-11 Sponsor Protocol Number: 2021-1798 Start Date*: 2021-09-09
    Sponsor Name:Rijnstate hospital
    Full Title: Ultrasound-guided radiofrequency ablation versus radioactive iodine as treatment for hyperthyroidism caused by solitary autonomous thyroid nodules.
    Medical condition: Patients > 18 years with (subclinical) hyperthyroidism caused by a solitary hyperactive thyroid nodules, either as a solitary hyperactive node in an otherwise normal thyroid gland or as a single hy...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004860 10043753 Thyroid nodule (toxic) LLT
    20.0 100000004860 10043791 Thyrotoxicosis from ectopic thyroid nodule LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 08:47:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA